The present invention relates to a cocrystal of ubiquinone and a hydrogen bond donor coformer, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The invention also relates to compositions comprising the cocrystal.

The present invention relates to a cocrystal of ubiquinone and a hydrogen bond donor coformer, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The invention also relates to compositions comprising the cocrystal.

The present invention relates to a co-crystal of coenzyme QH and nicotinamide, a preparation method therefor and the use thereof. Compared with the existing coenzyme QH, the co-crystal has a higher melting point and superior stability. The preparation method for the co-crystal of coenzyme QH is simple, easy to control and good in terms of reproducibility. The present invention greatly improves the use convenience of coenzyme QH, saves costs during storage, transportation and use, and broadens the application range of coenzyme QH.

The present invention relates to a co-crystal of coenzyme QH and nicotinamide, a preparation method therefor and the use thereof. Compared with the existing coenzyme QH, the co-crystal has a higher melting point and superior stability. The preparation method for the co-crystal of coenzyme QH is simple, easy to control and good in terms of reproducibility. The present invention greatly improves the use convenience of coenzyme QH, saves costs during storage, transportation and use, and broadens the application range of coenzyme QH.

It is an object of the present disclosure to provide a method for producing a reduced coenzyme Q10 Form II crystal or a crystalline solid thereof, which is excellent in the filterability of a slurry containing a reduced coenzyme Q10 Form II crystal.

The present embodiment is a method for producing a reduced coenzyme Q10 Form II crystal or a crystalline solid thereof, including: adding a reduced coenzyme Q10 Form II crystal as a seed crystal to a mixed solution containing an alcohol and a reduced coenzyme Q10; and precipitating a reduced coenzyme Q10 Form II crystal in the mixed solution after adding the seed crystal, wherein a change rate of formazin turbidity (FTU) is maintained at 15 FTU/min or more for 80% or more of a period during which the formazin turbidity (FTU) shifts from 1,000 to 10,000 in the precipitation.

The present invention in one embodiment provides a compound of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

The present invention in one embodiment provides a compound of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.

A process for producing reduced coenzyme Q.sub.10 includes removing moisture from an aqueous suspension including a reduced coenzyme Q.sub.10-containing microbial cell or a disrupted cell thereof such that a de-moisturized substance is obtained and in contact with an oxidizing atmosphere, and that an oxidized coenzyme Q.sub.10 is produced in an amount of 50 mass % or more relative to a total amount of the oxidized and reduced coenzymes Q.sub.10, and reducing the oxidized coenzyme Q.sub.10 outside a microbial cell such that a reduced coenzyme Q.sub.10 is recovered.

A process for producing reduced coenzyme Q.sub.10 includes removing moisture from an aqueous suspension including a reduced coenzyme Q.sub.10-containing microbial cell or a disrupted cell thereof such that a de-moisturized substance is obtained and in contact with an oxidizing atmosphere, and that an oxidized coenzyme Q.sub.10 is produced in an amount of 50 mass % or more relative to a total amount of the oxidized and reduced coenzymes Q.sub.10, and reducing the oxidized coenzyme Q.sub.10 outside a microbial cell such that a reduced coenzyme Q.sub.10 is recovered.

The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).